Related Experiment Video
Updated: May 5, 2026
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Clinical outcomes in systematic screening for atrial fibrillation (STROKESTOP): a multicentre, parallel group,
Emma Svennberg1, Leif Friberg2, Viveka Frykman2
1Karolinska Institutet, Department of Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden.
Insights
Systematic screening for atrial fibrillation in older adults demonstrated a small net benefit, reducing stroke and death. This approach is safe and effective for early detection and treatment in elderly populations.
Area of Science:
- Cardiology
- Geriatrics
- Public Health
Background:
- Atrial fibrillation is a major risk factor for ischemic stroke.
- Early detection and anticoagulant therapy can significantly reduce stroke risk and mortality.
- This study investigated the impact of systematic atrial fibrillation screening in an older population.
Purpose of the Study:
- To assess if systematic screening for atrial fibrillation reduces mortality and morbidity compared to no screening in individuals aged 75-76.
- To evaluate the safety and effectiveness of early atrial fibrillation detection through screening programs.
Main Methods:
- A multicenter, randomized controlled trial (STROKESTOP) involving 75-76-year-olds in Sweden.
- Participants were randomized to either an atrial fibrillation screening group or a control group.
- Screening involved a 14-day electrocardiogram (ECG) with oral anticoagulants offered upon detection.
Main Results:
- Over 28,000 individuals were randomized; 7,165 participated in screening (51.3%).
- After a median follow-up of 6.9 years, the screening group had fewer primary endpoint events (stroke, embolism, bleeding, death) than the control group (HR 0.96, p=0.045).
- The screening intervention showed a statistically significant, albeit small, net benefit.
Conclusions:
- Systematic screening for atrial fibrillation in older populations provides a small net benefit.
- The findings indicate that screening for atrial fibrillation is a safe and beneficial strategy in elderly individuals.
- Early detection and management of atrial fibrillation through screening can contribute to reducing adverse cardiovascular outcomes.
Background:
Atrial fibrillation is a leading cause of ischaemic stroke. Early detection of atrial fibrillation can enable anticoagulant therapy to reduce ischaemic stroke and mortality. In this randomised study in an older population, we aimed to assess whether systematic screening for atrial fibrillation could reduce mortality and morbidity compared with no screening.
Methods:
STROKESTOP was a multicentre, parallel group, unmasked, randomised controlled trial done in Halland and Stockholm in Sweden. All 75-76-year-olds residing in these two regions were randomly assigned (1:1) to be invited to screening for atrial fibrillation or to a control group. Participants attended local screening centres and those without a history of atrial fibrillation were asked to register intermittent electrocardiograms (ECGs) for 14 days. Treatment with oral anticoagulants was offered if atrial fibrillation was detected or untreated. All randomly assigned individuals were followed up in the intention-to-treat analysis for a minimum of 5 years for the primary combined endpoint of ischaemic or haemorrhagic stroke, systemic embolism, bleeding leading to hospitalisation, and all-cause death. This trial is registered with ClinicalTrials.gov, NCT01593553.
Findings:
From March 1, 2012, to May 28, 2014, 28 768 individuals were assessed for eligibility and randomly assigned to be invited to screening (n=14 387) or the control group (n=14 381). 408 individuals were excluded from the intervention group and 385 were excluded from the control group due to death or migration before invitation. There was no loss to follow-up. Of those invited to screening, 7165 (51·3%) of 13 979 participated. After a median follow-up of 6·9 years (IQR 6·5-7·2), significantly fewer primary endpoint events occurred in the intervention group (4456 [31·9%] of 13 979; 5·45 events per 100 years [95% CI 5·52-5·61]) than in the control group (4616 [33·0%] of 13 996; 5·68 events per 100 years [5·52-5·85]; hazard ratio 0·96 [95% CI 0·92-1·00]; p=0·045).
Interpretation:
Screening for atrial fibrillation showed a small net benefit compared with standard of care, indicating that screening is safe and beneficial in older populations.
Funding:
Stockholm County Council, the Swedish Heart & Lung Foundation, King Gustav V and Queen Victoria's Freemasons' Foundation, the Klebergska Foundation, the Tornspiran Foundation, the Scientific Council of Halland Region, the Southern Regional Healthcare Committee, the Swedish Stroke Fund, Carl Bennet AB, Boehringer Ingelheim, Bayer, and Bristol Myers Squibb-Pfizer.
Related Concept Videos
01:15Assessment of blood pressure in brachial artery(one-step method)
Prepare for the Procedure:
01:23Assessment of blood pressure in brachial artery(two-step method)
01:10Pre-Procedural Guidelines for Assessing Blood Pressure
01:27Regulation of Stroke Volume
Preload refers to the degree of stretch on the heart before it contracts. It's analogous to the stretching of a rubber band; the more it's stretched, the more forcefully it snaps back. This concept is encapsulated in the Frank-Starling law of the...
01:22Cardiac Output II: Effect of Stroke Volume on Cardiac Output
Preload
Preload refers to the initial elongation of the cardiac myocytes before contraction and is related to the volume of blood filling the heart at the end of diastole, or end-diastolic volume. The...
01:30Acute Coronary Syndrome III: Diagnostic Studies